ACRES and inVentiv Health Partner to Promote Operational Excellence and Shared, Global Clinical Research Platform
inVentiv Clinical Trial Recruitment Solutions and the Alliance for Clinical Research Excellence and Safety are partnering toward the development of a global system
inVentiv Clinical Trial Recruitment Solutions (iCTRS) and the Alliance for Clinical Research Excellence and Safety (ACRES) are partnering toward the development of a global system to support responsible conduct of clinical trials according to the highest standards of safety, quality and efficiency. The partnership between ACRES and inVentiv focuses on developing and adopting global standards and performance metrics as the basis for clinical research best practices and guidelines, and developing a global information platform for effective trial management. iCTRS brings expertise in global, data-driven decision support systems, advanced informatics technologies and a patient-centric approach for trial acceleration.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
